Clinical Trial Update: Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating open-label anecortave acetate sterile suspension (15 mg) for age-related macular degeneration with subfoveal neovascularization not mee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Manhattan Eye, Ear & Throat Hospital | Conditions: Age-Related Macular Degenerations., Subfoveal Neovascularization. | Phase 2 | Status: COMPLETED